NEW YORK (GenomeWeb News) – Anagnostics and Molzym today announced a licensing agreement and partnership to develop hybcell Pathogens DNA, a system for the rapid identification of sepsis-causing pathogens from whole blood.
Anagnostics will in-license Molzym's SepsiTest sample preparation and combine it with its compact sequencing technology for pathogen detection. SepsiTest is for DNA extraction from samples with low loads of pathogens. The DNA microbial enrichment method is based on Molzym's technology called MolYsis, which enables up to 40,000-fold DNA enrichment over conventional technologies, according to Anagnostics. MolYsis removes DNA from dead microbes, allowing for the timely monitoring of successful antibiotic treatment.
Additionally, Anagnostics said that because the technology being developed will use whole blood, the need for microbiological breeding can be circumvented and test results can be achieved in four hours, compared to one or more days with other methods.
The first tests will be available in the late fall.
Anagnostics, based in St. Valentin, Austria, develops tests and systems aimed at the pharmaceutical and clinical diagnostics spaces. On Thursday, it announced genXpress Service & Vertriebs as its distributor in Austria. Molzym, based in Bremen, Germany, manufactures products for molecular diagnostics with a focus on technologies for the selective isolation of pathogen DNA from clinical specimens.